Cytowave LLC, is a biotech company which offers a new approach in helping to treat the injuries and greatly accelerate healing in race and performance horses. This is achieved by combining three state-of-the art discoveries in physics, biophysics and electronics: SQUID-based (Superconductive Quantum Interference Device) signal development, high precision ultrasound and 3-D reconstruction of the target tissues before and after the treatment.
Interview with Frank Lyman of Cytowave
Background
Cytowave, LLC. was founded in 2006 by Richard Parker, who developed the first research model applicator in 2010 and pioneered the use of SQUID signals in treating equine injuries. This SQUID design resulted from a previous 11-year research and clinical application program, which involved treating over 700 human patients in the Bahamas, Costa Rica and Scandinavia.
The first exhibitions of SQUID treatment applications was with co-author Marko Markov, Ph.D., of New York at the Karolinska Institute in Stockholm, Sweden and at Olympiatoppen in Oslo, Norway, the training home of the International Olympic Committee. As a result, Richard received helpful suggestions that were folded into the current Model 1.0 of the system, projecting toward Model 2.0 and finally Model 3.0 a year later.
In 2010, the Company admitted additional investors, including attorney Denis Kleinfeld of Miami, FL., and Charles Johnston of Jupiter, FL., a successful businessman and philanthropist. In 2013, Frank Lyman, an experienced medical device executive, joined the Cytowave team as president.
In 2011, Richard travelled to Greece to acquire the first set of SQUID signals for use in the new Cytowave controller. A year later, the first SQUID signal trial was initiated in Madison, Wis., at the facilities of the University of Wisconsin. Signal analysis and processing is currently being advanced by a former analyst at Lawrence Livermore Laboratory, who specialized in ASW acoustic submarine-detection patterns (Note – the laboratory itself is not directly involved in our research).
Cytowave Back application
Cytowave therapy on the back of a horse
Following frustration at FDA delays and administrative processes, an equine study commenced in December 2012, and concluded in December 2013. Approximately fifty horses were treated and 25 studies completed with candidates from Calder, Gulfstream, Santa Anita and Belmont race tracks under actual every-day conditions involving training staff.
http://cytowave.com/product/about/
Call for more information: 844-298-9283